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 فقدان التوازن يف عوامل النسخ للخلية التائية يف مرضى التهاب الدرقية
املنسوب هلاشيموتو
فاهد �سفدري، اإبراهيم علي جاين، مرمي نعمتي، عبداهلل جعفر زاده
abstract: Objectives: Imbalances in effector T cell functioning have been associated with a number of 
autoimmune diseases, including Hashimoto’s thyroiditis (HT). Differentiation of effector T helper (Th) 1, Th2, Th17 
and regulatory T cell (Treg) lymphocytes is regulated by transcription factors, including Th1-specific T box (T-bet), 
GATA binding protein-3 (GATA3), retinoid-related orphan receptor (ROR)-α and forkhead box P3 (FOXP3). This 
study aimed to investigate Th1/Th2, Th1/Treg, Th2/Treg and Th17/Treg balances at the level of these transcription 
factors. Methods: This study took place between October 2015 and August 2016. Peripheral blood mononuclear 
cells were collected from a control group of 40 healthy women recruited from the Zahedan University of Medical 
Sciences, Zahedan, Iran, and a patient group of 40 women with HT referred to the Hazrat Ali Asghar Hospital, 
Zahedan. Total ribonucleic acid extraction was performed and the gene expression of transcription factors was 
quantitated using a real-time polymerase chain reaction technique. Results: Expression of T-bet and GATA3 was 
significantly elevated, while FOXP3 expression was significantly diminished among HT patients in comparison with 
the controls (P = 0.03, 0.01 and 0.05, respectively). Expression of RORα was higher among HT patients, although 
this difference was not significant (P = 0.15). Expression of T-bet/FOXP3, GATA3/FOXP3 and RORα/FOXP3 
ratios were increased among HT patients in comparison with the controls (P <0.02, <0.01 and <0.01, respectively). 
Conclusion: These results indicate that HT patients have imbalances in Th1/Treg, Th2/Treg and Th17/Treg 
lymphocytes at the level of the transcription factors, deviating towards Th1, Th2 and Th17 cells. Correction of these 
imbalances may therefore be therapeutic. 
Keywords: Hashimoto Thyroiditis; Transcription Factors; Lymphocytes; Th1 Cells; Th2 Cells; Th17 Cells; Regulatory 
T Cells.
امللخ�ص: الهدف: فقدان التوازن يف فعالة اخللية امل�ستفعلة التائية قد اأرتبطت بعدد من اأمرا�س املناعة الذاتية مبا فيها التهاب الدرقية 
املن�سوب لها�سيموتو. التفريق بني م�ستفعالت اخللية التائية امل�ساعدة 1، 2، 17، واخللية اللمفاوية التائية املنظمة ينظم عن طريق عوامل 
الن�سخ مبا فيها حمدد �سندوق التائية امل�ساعدة 1، الربوتني الرابط GATA3، وغريها. تهدف هذة الدرا�سة اإىل التحقق من توازن اخلاليا 
التائية امل�ساعدة 1، 2، 17، وامل�ستفعلة على م�ستوى عوامل الن�سخ. الطريقة: اإجريت هذة الدرا�سة بني اأكتوبر 2015 و اأغ�سط�س 2016. مت 
جمع خاليا اأحادية النواة من الدم املحيطي ملجموعة التحكم املكونة من 40 إمراأة �سليمة �سحيا ومت اأختيارهن من جامعة زهدان للعلوم 
الطبية، زهدان، اإيران، وجمموعة املر�سى املكونة من 40 امراأة م�سابات بالتهاب الدرقية املن�سوب لها�سيموتو واملحوالت من م�ست�سفى 
زهرة علي اأ�سغر، زهدان. مت اإجراء ا�ستخال�س حام�س الريبونيوكلييك وتقديرالتعبري اجليني لعوامل الن�سخ باإ�ستخدام تقنية الوقت احلايل 
لبوليمرياز التفاعل الت�سل�سلي. النتائج: كان تعبري حمدد �سندوق التائية امل�ساعدة والربوتني الرابط GATA3 مرتفع ب�سكل ملحوظ، بينما 
كان تعبري FOXP3 منخف�س ب�سكل ملحوظ يف مر�سى التهاب الدرقية املن�سوب لها�سيموتو مقارنة مبجموعة التحكم ) على التوايل 0.05 
 .)P = 0.15( كان مرتفعا عند مر�سى التهاب الدرقية املن�سوب لها�سيموتو لكن الفارق مل يكن معتدا RORα تعبري .)P <0.03, <0.01 و
ن�سبة التعبري كانت مرتفعة يف RORα /FOXP3 و T-bet/FOXP3 ،GATA3/FOXP3 يف مر�سى التهاب الدرقية املن�سوب لها�سيموتو 
مقارنة مبجموعة التحكم )على التوايل 0.01> و P <0.02, <0.01(. اخلال�صة: ت�سري هذة النتائج اإىل اأن مر�سى التهاب الدرقية املن�سوب 
لها�سيموتو لديهم فقدان التوازن يف اخلاليا اللمفاوية التائية امل�ساعدة 1، 2، 17، والتائية املنظمة عند م�ستوى عوامل الن�سخ والتحول جلهة 
هذة اخلاليا. ت�سحيح هذا التوازن قد يكون له دور عالجي.
الكلمات املفتاحية: التهاب الدرقية املن�سوب لها�سيموتو؛ عوامل الن�سخ؛ اللمفاويات؛ خاليا تائية م�ساعدة 1؛ خاليا تائية م�ساعدة 2؛ خاليا تائية م�ساعدة 
17؛ خاليا تائية منظمة.
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Advances in Knowledge
- The results of the current study indicate that patients with Hashimoto’s thyroiditis (HT) have T helper (Th) 1/regulatory T cell (Treg), 
Th2/Treg and Th17/Treg cell imbalances at the level of the transcription factors, with a deviation towards Th1, Th2 and Th17 cells. 
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Hashimoto’s thyroiditis (HT) is one ofthe most prevalent organ-specific and T cell- mediated disorders worldwide and predom- 
inantly affects women, with approximately 4–10 women 
developing the disease for every one man.1 
Pathologically, HT is characterised by the homing of a 
number of leukocytes—such as cluster of differentiation 
(CD) 4+ T cells, cytotoxic T lymphocytes, B cells and 
natural killer cells—to the thyroid gland.2 These 
leukocytes then proceed to kill thyroid follicular cells 
via antibody-dependent cytotoxicity and/or apoptosis.2 
Serologically, anti-thyroid antibodies, especially 
anti-thyroglobulin (TG) and anti-thyroperoxidase 
(TPO), have been positively associated with more 
severe thyroid inflammation and the development of 
hypothyroidism.3 Many immunological abnormalities 
have been reported in patients with hypothyroidism.4 
Autoreactive CD4+ T helper (Th) lymphocytes play a 
major role in the pathogenesis of HT.3 The antigenic 
determinants of thyroglobulin are present on the 
surface of antigen-presenting cells and are recognised 
by specific CD4+ T cells.5 Following antigenic 
stimulation, different effector CD4+ T cells are 
differentiated from naïve T cells, including Th1, Th2, 
Th17 or regulatory T cell (Treg) lymphocytes, which 
produce different cytokines.5,6 
Among patients with HT, Th1 lymphocytes are 
the predominant cells in thyroid tissue.3 Th1 cells 
mainly produce interferon (IFN)-γ, which triggers cell-
mediated immunity.7 The master transcription factor 
of Th1 cells is Th1-specific T box (T-bet).6 Th2 cells 
produce interleukin (IL)-4, IL-5, IL-6 and IL-13, which 
are involved in the induction of humoral immune 
responses.7,8 For Th2 cells, the master transcription 
factor is GATA binding protein-3 (GATA3).
6 Th2 
lymphocytes may contribute to thyroiditis through 
the stimulation of B cells, which produce antibodies 
against thyroid antigens.3 Th17 cells secrete a number 
of cytokines, particularly IL-17 (also known as IL-17A), 
IL-17F, IL-21, IL-22, tumour necrosis factor-α 
and granulocyte macrophage colony-stimulating 
factor.9,10 Th17 cells are involved in the induction of 
inflammatory responses.11,12 Retinoid-related orphan 
receptor (ROR)-γt and RORα serve as the transcription 
factors of Th17 cells.12,13 Elevated numbers of Th17 
cells have been indicated in patients with HT.3 Treg 
cells play a major role in the establishment of immune 
tolerance through the secretion of immunoregulatory 
cytokines such as transforming growth factor (TGF)-β, 
IL-10 and IL-35.14 Treg cell functions depend on the 
expression of forkhead box P3 (FOXP3).14,15 Treg cells 
play a protective role against thyroid autoimmune 
diseases, with Treg cell depletion shown to promote 
experimental autoimmune thyroiditis in mice.16,17
A balanced ratio of Th1/Th2, Th1/Treg, Th2/Treg 
and Th17/Treg cells is required for normal immune 
function; as such, imbalances in effector T cell 
functioning have been associated with a number of 
autoimmune diseases.12,13,18 Functionally, Th1 and Th2 
cells inhibit each other at the level of the transcription 
factors, with Th17 and Treg cells similarly inhibiting one 
another.19,20 Although a few studies have investigated 
transcription factors among HT patients, few have 
measured Th1/Th2, Th1/Treg, Th2/Treg and Th17/
Treg cell balances at the level of these transcription 
factors.21,22 This study therefore aimed to determine the 
balance of effector T cells—specifically, Th1, Th2, Th17 
and Treg cells—at the level of transcription factors by 
measuring the expression of their master transcription 
factors—T-bet, GATA3, RORα/RORγt and FOXP3, 
respectively—and determining their ratios in the 
peripheral blood mononuclear cells (PBMCs) of HT 
patients in comparison to healthy individuals.
Methods
This study was conducted from October 2015 to 
August 2016 and included both HT patients and 
healthy individuals. The patient group consisted 
of 40 women with HT referred to the Hazrat Ali 
Asghar Hospital, Zahedan, Iran. A diagnosis of 
HT was made by expert endocrinologists based on 
commonly accepted clinical and laboratory criteria, 
including positive results for anti-TG and/or anti-
TPO antibodies at high titres and evidence of thyroid 
dysfunction on a sonogram.23 At the time of the 
study, none of the patients were receiving antithyroid 
drugs, thyroid hormone replacement therapy or any 
- According to these findings, a combination of Th1, Th2 and Th17 cell-related immune responses may synergistically contribute to the 
pathogenesis of HT.
Application to Patient Care
- As HT patients in the current study were found to have Th1/Treg, Th2/Treg and Th17/Treg imbalances, correction of these imbalances 
may provide immunotherapeutic benefits for these patients.
- Since Th1-specific T box (T-bet), retinoid-related orphan receptor (ROR)-α and forkhead box P3 (FOXP3) are the specific transcription 
factors for Th1, Th17 and Treg cells, respectively, the expression of T-bet/FOXP3, GATA binding protein-3/FOXP3 and RORα/FOXP3 
messenger ribonucleic acid ratios may be a useful surrogate parameter to determine Th1/Treg, Th2/Treg and Th17/Treg cell status 
among HT patients. 
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immunomodulatory or anti-inflammatory treatments. 
The control group comprised 40 healthy women who 
were recruited from members of staff at the Zahedan 
University of Medical Sciences, Zahedan. None of 
the healthy controls had thyroiditis or other relevant 
diseases or were currently suffering from any acute or 
chronic illnesses. 
A total of 10 mL of peripheral blood was taken 
from each subject and stored at -20 °C. Thyroid hormones 
and autoantibodies were measured by assessing serum 
concentrations of triiodothyronine (T3), thyroxine 
(T4) and thyroid-stimulating hormone (TSH) using 
a commercial radioimmunoassay kit (Kavoshyar Iran 
Co., Tehran, Iran). Normal ranges were considered to 
be 80.0–190.0 ng/dL, 4.5–12.0 μg/dL and 0.3–4.0 μU/mL 
for T3, T4 and TSH, respectively.24 Anti-TG and anti-
TPO antibodies were measured using a rapid enzyme-
linked immunosorbent assay (Genesis Diagnostics Ltd., 
Ely, UK). Positive anti-TG and anti-TPO concentrations 
were defined as >100.0 IU/mL and >75.0 IU/mL, 
respectively.24 
The peripheral blood samples were then hepa-
rinised and loaded into a lymphocyte separation 
media (Lymphosep®, Biosera, Labtech International 
Ltd., Uckfield, UK). Subsequently, the PBMCs were 
separated by gradient centrifugation and the total 
ribonucleic acid (RNA) extracted using a reagent 
(TRIzol®, ThermoFisher Scientific Inc., Waltham, 
Massachusetts, USA), according to the manufacturer’s 
guidelines. Electrophoresis in ethidium bromide 
pretreated agarose gel was used to determine the 
quality of the extracted RNA; purity was determined 
by measuring absorption using a spectrophotometer 
to achieve a ratio of 260:280. In order to prepare the 
extracted RNA for quantification using a real-time 
polymerase chain reaction (PCR) technique, it was first 
converted to a complementary DNA template using 
a synthesis kit (Bioneer Corp., Daejeon, South Korea) 
containing both oligo-deoxythymidine and random 
hexamer primers. The reverse transcription protocol 
involved 10 minutes at 70 °C, then one minute at 
20 °C to cool, followed by the addition of the reverse 
transcription enzyme, incubation at 42 °C for 60 
minutes and finally incubation at 95 °C for 10 minutes 
to halt activation of the reverse transcription enzyme.
Real-time PCR was carried out three times 
with a thermal cycler (Corbett Rotor-Gene 6000, 
ThermoFisher Scientific Inc.) using a PCR master 
mix (SYBR Green I, Bioneer Corp.) that was mixed 
with 200 ng of complementary DNA and 2 µL of each 
primer (5 pmol/µL) [Table 1]. The thermal cycling 
conditions entailed 15 minutes at 95 °C as an initial 
denaturing step, 40 cycles for 30 seconds at 95 °C as a 
secondary denaturing step, 40 cycles for 30 seconds at 
60 °C for annealing and extension and finally 40 cycles 
for 30 seconds at 72 °C. A housekeeping gene (β-actin) 
was applied to normalise the data. The quantity of 
expression of the transcription factors was calculated 
using the 2-ΔΔCt formula and expressed as units 
relative to the amount of the β-actin gene expression. 
The dissociation process, melting curves and data 








T-bet = Th1-specific T box; GATA3 = GATA binding protein-3; RORα = retinoid-related orphan receptor-α; FOXP3 = forkhead box P3.
Table 2: Messenger ribonucleic acid expression of 
effector T cell-specific transcription factors using the 
peripheral blood mononuclear cells of female healthy 
controls and patients with Hashimoto’s thyroiditis from 
Zahedan, Iran (N = 80)
Transcription 
factor








T-bet 1.06 ± 0.18 2.08 ± 0.43 0.03
GATA3 1.02 ± 0.15 1.94 ± 0.32 0.01
RORα 1.00 ± 0.16 1.39 ± 0.24 0.15
FOXP3 1.00 ± 0.38 0.35 ± 0.09 0.05
T-bet/GATA3 1.58 ± 0.27 1.26 ± 0.22 0.36
GATA3/FOXP3 6.48 ± 2.90 13.30 ± 2.42 0.01
T-bet/FOXP3 10.59 ± 5.26 29.37 ± 12.87 0.02
RORα/FOXP3 6.36 ± 2.15 12.46 ± 3.06 0.01
mRNA = messenger ribonucleic acid; SE = standard error; 
HT = Hashimoto’s thyroiditis; T-bet = Th1-specific T box; 
GATA3 = GATA binding protein-3; RORα = retinoid-related orphan 
receptor-α; FOXP3 = forkhead box P3.
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quantitation were carried out using the thermal cycler 
software (Corbett Rotor-Gene 6000, ThermoFisher 
Scientific Inc.).
Gene expression amounts were presented as 
means ± standard error. The data were analysed 
statistically using a t-test. A P value of <0.05 was 
considered statistically significant. The Ethical 
Committee of the Kerman University of Medical 
Sciences, Kerman, Iran, approved this study (#K-
93-418). Moreover, informed written consent was 
obtained from all subjects prior to their participation.
Results
The mean ages of the HT patients and healthy 
controls were 38.6 ± 10.6 years and 36.1 ± 11.2 years, 
respectively (P = 0.32). Mean serum concentrations of 
T3, T4 and TSH were 25.7 ± 5.6 ng/dL, 2.8 ± 0.7 μg/dL 
and 7.2 ± 1.2 μU/mL, respectively, among HT patients 
and 105.0 ± 23.0 ng/dL, 8.2 ± 1.9 μg/dL and 1.8 ± 1.1 
μU/mL, respectively, among healthy controls (P <0.01 
each). All of the HT patients had hypothyroidism. 
The mean serum levels of anti-TG and anti-TPO 
were 543.1 ± 212.6 IU/mL and 283.6 ± 194.4 IU/mL, 
respectively, among HT patients and 16.7 ± 6.5 IU/
mL and 12.8 ± 4.5 IU/mL, respectively, among healthy 
controls (P <0.01 each).
Fold changes in the expression of the T-bet, 
GATA3, RORα and FOXP3 transcription factors and 
their ratios are shown in Table 2. Expression of T-bet 
and GATA3 was significantly higher among patients 
with HT in comparison to the control group (P = 0.03 
and 0.01, respectively). Although RORα expression was 
increased in the patient group, the difference between 
Figure 1: Charts showing the mean messenger ribonucleic acid (mRNA) expression of the (A) Th1-specific T box (T-bet)/
GATA binding protein-3 (GATA3) and (B) T-bet/forkhead box P3 (FOXP3) ratios using the peripheral blood mononuclear 
cells of female healthy controls and patients with Hashimoto’s thyroiditis (HT) from Zahedan, Iran (N = 80). The mRNA 
expression of the T-bet/GATA3 ratio was lower among the HT patients than the healthy controls; however, this difference 
was not significant (P = 0.36). In comparison, the mRNA expression of the T-bet/FOXP3 ratio was significantly higher 
among HT patients than the healthy controls (P <0.02).
T-bet = Th1-specific T box; GATA3 = GATA binding protein-3; mRNA = messenger ribonucleic acid; HT = Hashimoto’s thyroiditis; 
FOXP3 = forkhead box P3.
Figure 2: Charts showing the mean messenger ribonucleic acid (mRNA) expression of the (A) GATA binding protein-3 
(GATA3)/forkhead box P3 (FOXP3) and (B) retinoid-related orphan receptor (ROR)-α/FOXP3 ratios using the peripheral 
blood mononuclear cells of female healthy controls and patients with Hashimoto’s thyroiditis (HT) from Zahedan, Iran 
(N = 80). The mRNA expression of both the GATA3/FOXP3 and RORα/FOXP3 ratios was significantly higher among HT 
patients than the healthy controls (P <0.01 each).
GATA3 = GATA binding protein-3; FOXP3 = forkhead box P3; mRNA = messenger ribonucleic acid; HT = Hashimoto’s thyroiditis;
RORα = retinoid-related orphan receptor-α.
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HT patients and the healthy control group was not 
significant (P = 0.15). Expression of FOXP3 among HT 
patients was significantly downregulated as compared 
with the control group (P = 0.05). No significant 
difference was observed between HT patients and the 
control group regarding the mean messenger RNA 
(mRNA) expression of the T-bet/GATA3 ratio [Figure 
1A]. However, mean mRNA expression of the T-bet/
FOXP3, GATA3/FOXP3 and RORα/FOXP3 ratios 
was significantly higher among patients with HT in 
comparison with the healthy control group (P <0.02, 
<0.01 and <0.01, respectively) [Figures 1B and 2].
Discussion
A number of studies have demonstrated alterations 
in the frequency and/or function of effector CD4+
T cells among HT patients.3,25,26 However, the molecular 
mechanisms of these changes remain unclear. The 
results of the current study show that expression of 
T-bet, the Th1 transcription factor, was significantly 
higher among HT patients than in the healthy control 
group. Th1 cells are induced in response to IFN-γ and 
IL-12, which are secreted primarily by dendritic and 
natural killer cells, respectively.6 IFN-γ- and IL-12-
related signal pathways are mediated through signal 
transducer and activator of transcription (STAT) 1 
and STAT4, which cause T-bet expression; T-bet 
then induces IFN-γ production, strengthening Th1 
polarisation and forming a positive feedback loop.6 
Higher levels of IFN-γ and IL-12 have been reported 
among patients with HT, which may account for the 
increased expression of T-bet in these patients.27,28 
It seems that HT is a Th1-dependent process in that 
the IFN-γ-secreting Th1 cells activate cytotoxic 
T lymphocytes and macrophages, killing thyroid 
follicular cells.28
The current study also demonstrated that 
expression of GATA3, the Th2 transcription factor, 
was significantly increased among HT patients as 
compared to the healthy controls. Differentiation 
of Th2 cells is induced by IL-4, which is secreted 
primarily by mast cells and basophils.8 The IL-4-
related signal pathway is mediated through STAT6, 
which causes GATA3 expression, thus inducing the 
production of Th2-type cytokines and self-activation 
in a self-reinforcing cycle.6 The elevated expression 
of IL-4 has been previously reported among patients 
with HT, which may explain the increased expression 
of GATA3 among these patients.
29 However, no 
significant difference was noted between HT patients 
and the control group in the current study regarding 
expression of the T-bet/GATA3 ratio; this suggests 
that both Th1 and Th2 cell-related immune responses 
may contribute to the pathogenesis of HT. Qin et al. 
demonstrated increased expression of Th1-related 
cytokines in both the thyroid gland and PBMCs of 
HT patients.30 Moreover, increased expression of Th1-
related cytokines has been associated with elevated 
titres of anti-TPO antibodies, the destruction of 
thyroxisomes and the induction of apoptosis in thyroid 
follicular cells.31–33 However, the importance of the role 
of Th2 cells in the pathogenesis of HT is still debatable.
Expression of FOXP3, the Treg cell transcription 
factor, was significantly reduced among patients with 
HT in comparison with the healthy control group 
in the current study. Treg cells are divided into two 
subgroups—natural Treg and inducible Treg cells.14,15 
The former are generated from precursor cells in 
the thymus, whereas antigenic stimulation in the 
presence of TGF-β and IL-2 causes differentiation 
of naïve CD4+ T cells into the latter cells in the 
peripheral lymphoid organs.14,15 Indeed, lower levels 
of TGF-β have been reported among patients with 
HT, potentially accounting for their decreased FOXP3 
expression.34 The findings of the present study suggest 
that the downregulation of Treg cell-related functions 
may contribute to HT pathogenesis. Moreover, 
diminished numbers of Treg cells and low gene 
expression of FOXP3 in PBMCs has previously been 
reported among HT patients.35,36 Certain Treg cell-
related cytokines (TGF-β, IL-10 and IL-35) have been 
associated with low-grade thyroid inflammation and 
an improvement in HT symptoms.26 However, another 
study demonstrated FOXP3 upregulation in the T cells 
of peripheral blood samples from patients with HT.21 
This discrepancy is perhaps attributable to differing 
inclusion criteria used in these studies.21,35,36
In the current study, expression of the T-bet/
FOXP3, GATA3/FOXP3 and RORα/FOXP3 ratios was 
significantly increased among patients with HT in 
comparison with the healthy control group; however, 
while the expression of T-bet, GATA3 and RORα 
alone was increased, FOXP3 expression alone was 
reduced among HT patients. Therefore, it is logical 
that expression of the T-bet/FOXP3, GATA3/FOXP3 
and RORα/FOXP3 ratios was significantly increased 
among the HT patients. Xue et al. reported that the 
Treg/Th17 ratio among HT patients was significantly 
decreased when compared with a euthyroid control 
group.35 These findings indicate that imbalances 
in Th1/Treg, Th2/Treg and Th17/Treg cells at the 
level of transcription factors may contribute to the 
pathogenesis of HT, with a tendency towards Th1, 
Th2 and Th17 cells. As such, the correction of these 
imbalances may be of immunotherapeutic benefit for 
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affected patients. As STAT5 and STAT3 regulate the 
differentiation of Treg and Th17 cells, respectively, 
the suppression of STAT3 by small interfering RNA 
molecules has been found to significantly reduce 
Th17 cells and increase Treg cells in the CD4+ T 
cells of patients with rheumatoid arthritis.13 Similar 
immunotherapeutic strategies may be considered 
for the treatment of HT. Additionally, T-bet/FOXP, 
GATA3/FOXP3 and RORα/FOXP3 ratios may be 
useful surrogate parameters to determine the status 
of Th1/Treg, Th2/Treg and Th17/Treg cells in 
affected patients.
Increased IL-6 expression has been reported 
among patients with HT.37 In the presence of IL-6 
and TGF-β, the antigenic induction of naïve CD4+ 
T cells results in expression of RORγt and RORα 
(transcription factors of Th17 cells) via STAT3.11,13 
Pyzik et al. also observed increased numbers of Th17 
cells and elevated Th17-related cytokines among 
patients with HT, highlighting the role of Th17 in 
HT pathogenesis.3 In the present study, there was no 
significant difference between HT patients and the 
healthy group regarding RORα expression, although 
expression was higher among HT patients. No study 
has yet investigated expression of RORα in patients 
with HT; however, Shi et al. reported increased 
RORγt among HT patients.22 It is possible that 
RORα plays a less important role than RORγt in the 
development of Th17 cells. Noack et al. demonstrated 
that knocking out the RORα and RORγt genes 
disturbed differentiation of naïve CD4+ T cells to Th17 
lymphocytes; however, knocking out the RORγt gene 
exhibited more powerful consequences, suggesting 
that the RORγt gene plays a more important role in 
this process.13
Initially, HT was believed to be a Th1-mediated 
disease; however, recent data suggest that Th17 cells 
may play a more prominent role in HT pathogenesis.3,25 
The results of the current study suggest that a 
combination of Th1, Th2 and Th17 cell-related 
immune responses may synergistically contribute to 
the pathogenesis of HT. However, further research is 
needed to determine which Th subset plays a more 
important role in the development of HT. Recently, 
increased expression of FOXP3 and T-bet was 
demonstrated among HT patients who were severely 
affected but not euthyroid.21 Thus, it seems that 
different immunopathological mechanisms may be 
involved in the various expressions of the spectrum of 
HT-associated diseases. Moreover, thyroid function 
may also influence the expression of T cell-related 
transcription factors in HT patients.21 
Conclusion
The results of the current study indicate that HT 
patients have imbalances in Th1/Treg, Th2/Treg and 
Th17/Treg cells at the level of transcription factors, 
with a deviation towards Th1, Th2 and Th17 cells. Since 
T-bet, RORα and FOXP3 are specific transcription 
factors for Th1, Th17 and Treg cells, respectively, 
the expression of T-bet/FOXP, GATA3/FOXP3 and 
RORα/FOXP3 mRNA ratios may be considered useful 
surrogate parameters to determine the status of Th1/
Treg, Th2/Treg and Th17/Treg cells in such patients.
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